Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ACER Acer Therapeutics
0.750-0.010-1.32%
Close
03/30 16:00 ET
0.751+0.001+0.17%
Post Mkt Price 03/30 17:25 ET
High
0.785
Open
0.760
Turnover
241.12K
Low
0.735
Pre Close
0.760
Volume
321.54K
Post
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Research Analysts Set Expectations for Acer Therapeutics Inc.'s Q2 2023 Earnings (NASDAQ:ACER)
Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) – Equities research analysts at HC Wainwright issued their Q2 2023 earnings per share (EPS) estimates for Acer Therapeutics in a research report iss
Acer Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Acer Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Acer Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Acer Therapeutics (NASDAQ:ACER) with a Buy and maintains $12 price target.
H.C. Wainwright Sticks to Their Buy Rating for Acer Therapeutics (ACER)
Acer: Cash and Cash Equivalents Available at Dec 31, Gross Proceed of $7.0M From Loan, $4.1M From ATM Facility Loans to Dec 31, $2.7M From Sale of Securities Are Equivalents to Fund Operating and Cap Requirements Into Middle 2Q >ACER
Acer: Cash and Cash Equivalents Available at Dec 31, Gross Proceed of $7.0M From Loan, $4.1M From ATM Facility Loans to Dec 31, $2.7M From Sale of Securities Are Equivalents to Fund Operating and
Acer Therapeutics: Ended 4Q With $2.3M in Cash and Cash Equivalents >ACER
Acer Therapeutics 4Q Loss $9.4M >ACER
Press Release: Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutic
Acer Therapeutics Q4 EPS $(0.54) Misses $(0.37) Estimate
Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.37) by 45.95 percent. This is a 74.19 percent decrease over losses of
Acer Therapeutics 4Q Loss/Shr 54c >ACER
Acer Therapeutics 4Q Loss/Shr 54c >ACER
